About My Health Partner

Our mission

Our mission

Empower the patient in the daily management of his/her chronic disease, by providing information about the pathology and offering daily activities and recipes to reduce risks of cardiovascular events.
Our essence

Our essence

Servier puts the patient at the core of its activity. Creating innovative tools to help patients enhance their lives is our key challenge.
Our promise

Our promise

Provide personalized, certified, and updated content for patients with multiple cardiovascular risks to have a healthier life.

Why myhealth-partner.com ?

An estimated 17.9 million people died from CVDs in 2016, representing 31% of all global deaths.1 Because most CVDs can be prevented, people with cardiovascular disease or who are high cardiovascular risk (due to the presence of one or more risk factors such as hypertension, diabetes…) need reliable and certified content that is dynamic, with personalized advice according to their diseases and interests.
Myhealthpartner.com will select and suggest specific content for you, based on its relevance to your own conditions, via specific questions during the first visit to the platform (age, lifestyle, conditions, etc). No personal data is recorded, and some of the content of the platform will be automatically customized according to your answers.

About Servier

Servier is a global pharmaceutical group governed by a Foundation. Relying on a solid geographical presence and revenue of €4.7 billion in 2020 achieved in 150 countries, Servier employs 22,500 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities, from research to support beyond the pill.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.
Developed in consultation with The Global Heart Hub
Developed and approved by experts : Therapeutic aera experts, patient organizations and nutritionists.
Report a side effect with a Servier drugLast modified date: 4/1/2022